FBR analyst Vernon Bernardino is out today with a research note on Aurinia Pharmaceuticals Inc (NASDAQ:AUPH), providing insights from Aurinia’s Key Opinion Leader (KOL) breakfast …
Yesterday, Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) presented data at the European Lupus Meeting, which indicates 70% of patients achieved complete remission (CR) at 24 …
FBR Capital analyst Vernon Bernardino was out pounding the table on Aurinia Pharmaceuticals Inc (NASDAQ:AUPH), reiterating an Outperform rating and price target of $9.00, after …
Analysts offer insights into a volatile biotech-verse amid Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares dipping on news of a program termination and Aurinia Pharmaceuticals (NASDAQ:AUPH) soaring on …
Investors in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) should be smiling from ear to ear today after the company announced positive 24-week data in 10 patients from …
H.C.
FBR analyst Vernon Bernardino was out with a research note on shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) after the company announced updated results from its AURALV Phase …
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) investors cheer the news that the company’s lupus nephritis drug voclosporin met the primary and all pre-specified secondary endpoints in …
